Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to SEBI LODR Regulations

Audit Opinion:

The Limited Review Report issued by the Statutory Auditors, T R Chadha & Co LLP, contained no modifications or qualifications. Nothing came to their attention that causes them to believe that the accompanying Statement contains any material misstatement.

Key Financial Highlights [in Million except per share data]:

Standalone Results:

Revenue from Operations: ₹2,537.91 million (Q1 FY27) vs ₹2,365.64 million (Q1 FY26) - 7.3% YoY increase

Total Income: ₹2,590.66 million (Q1 FY27) vs ₹2,421.77 million (Q1 FY26)

Net Profit: ₹250.66 million (Q1 FY27) vs ₹256.95 million (Q1 FY26) - 2.4% YoY decrease

EPS: ₹2.33 (Basic and Diluted) for Q1 FY27 vs ₹2.39 for Q1 FY26

Consolidated Results:

Revenue from Operations: ₹3,312.24 million (Q1 FY27) vs ₹2,964.26 million (Q1 FY26) - 11.7% YoY increase

Total Income: ₹3,386.38 million (Q1 FY27) vs ₹3,034.34 million (Q1 FY26)

Net Profit: ₹104.96 million (Q1 FY27) vs ₹76.78 million (Q1 FY26) - 36.7% YoY increase

EPS: ₹0.98 (Basic and Diluted) for Q1 FY27 vs ₹0.71 for Q1 FY26

Profit attributable to Shareholders of the Group: ₹108.45 million (Q1 FY27) vs ₹89.22 million (Q1 FY26)

Segment-wise Performance:

The Group has two reportable segments:

Healthcare Services Segment:

Revenue: ₹2,888.14 million (Q1 FY27) vs ₹2,683.63 million (Q1 FY26)

Segment Results: ₹311.76 million profit (Q1 FY27) vs ₹325.67 million profit (Q1 FY26)

Manufacturing & Trading of Implants Segment:

Revenue: ₹424.10 million (Q1 FY27) vs ₹280.62 million (Q1 FY26)

Segment Results: ₹(114.81) million loss (Q1 FY27) vs ₹(99.15) million loss (Q1 FY26)

Corporate Actions:

No dividend declarations, share splits, bonus issues, buybacks, or capital structure changes were announced.

Appointment of Whole-Time Director:

The Board approved the appointment of Mr. Shanay Vikram Shah (DIN: 02726541) as an Additional Director designated as Whole-Time Director for a term of five consecutive years with effect from August 12, 2026. He shall also be designated as a Key Managerial Personnel. His appointment is subject to shareholder approval at the ensuing 22nd Annual General Meeting scheduled for September 10, 2026.

Mr. Shanay Vikram Shah is 35 years old, holds a Bachelor's degree in Science with Honors in Accounting and Finance from the University of Warwick, UK, a Master's degree in International Health Management from Imperial College London, UK, and is a Chartered Financial Analyst (CFA). He is one of the Promoters of the Company and is related to Dr. Vikram I. Shah (Chairman and Managing Director), being his son. He has been associated with the Company since October 5, 2013.

Appointment of Internal Auditors:

The Board approved the appointment of M/s. PricewaterhouseCoopers Services LLP, Chartered Accountants, as Internal Auditors of the Company for the financial year 2026-27.

Cost Audit Report:

The Board considered and approved the Cost Audit Report on the cost records of the Company for the financial year ended March 31, 2026, issued by M/s. Borad Sanjay B & Associates, Cost Accountants.

Acquisition of Shares:

Shalby Medtech Limited (wholly-owned subsidiary) acquired 10,000 equity shares representing 0.67% equity share capital of Shalby Global Technologies Pte. Ltd., Singapore (step-down subsidiary) from Dr. Vikram Shah and Mr. Shanay Shah for a cash consideration of SGD 2 per share (aggregating SGD 20,000).

Post-acquisition, Shalby Global Technologies Pte. Ltd. became a wholly-owned subsidiary of Shalby Medtech Limited effective August 12, 2026. The transaction was classified as a related party transaction but conducted at arm's length based on a valuation report from a SEBI-registered Category I Merchant Banker.

Shalby Global Technologies Pte. Ltd. is incorporated in Singapore and engaged in the business of Wholesale of medical, professional, scientific and precision equipment. Its turnover for FY 2025-26 was SGD 9,11,671.

Annual General Meeting:

The Board approved the Notice for convening the 22nd Annual General Meeting of members scheduled for Thursday, September 10, 2026, at 4:00 p.m. IST.

Other Significant Information:

The consolidated financial results include the results of the Company and 13 subsidiary companies (covering 3 step-down subsidiaries).

Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. As of June 30, 2026, the company has granted all 7,00,000 Stock Options to eligible employees, out of which 4,42,765 Stock Options were lapsed and 2,16,235 options were vested and exercised.

The company has granted 1,33,000 stock options from the pool of lapsed options. As of June 30, 2026, a total of 1,10,000 stock options remain active.

Shalby Medtech Limited has implemented its own Employee Stock Option Scheme and granted 50,000 Stock Options during the quarter ended June 30, 2026. As of June 30, 2026, SMTL has granted total 11,41,000 Stock Options.

The company is not a Large Corporate as per SEBI circular dated November 26, 2018.